M Lloret1,2,3, L García-Cabrera4, M Zajac4, P C Lara5,6,7. 1. Department of Radiation Oncology, Dr. Negrin Hospital, Barranco de La Ballena s/n, 35010, Las Palmas de Gran Canaria, Spain. mllosae@gobiernodecanarias.org. 2. Universidad de Las Palmas de Gran Canaria, Las Palmas, Spain. mllosae@gobiernodecanarias.org. 3. Instituto Canario de Investigación del Cáncer, Las Palmas de Gran Canaria, Spain. mllosae@gobiernodecanarias.org. 4. Department of Radiation Oncology, Dr. Negrin Hospital, Barranco de La Ballena s/n, 35010, Las Palmas de Gran Canaria, Spain. 5. Instituto Canario de Investigación del Cáncer, Las Palmas de Gran Canaria, Spain. 6. Universidad Fernando Pessoa Canarias, Las Palmas, Spain. 7. Department of Oncology, Hospital Universitario San Roque, Las Palmas, Spain.
Abstract
PURPOSE: The aim of this study is to assess for the first time, the role of regional deep hyperthermia in combination with radiotherapy and systemic therapy in patients with poor prognosis of brain metastases (GPI ≤ 2.5). METHODS: Patients with confirmed cerebral metastases and classified as GPI score ≤ 2.5 were included in this prospective study. Pretreatment stratification was defined as patients with 0-1 GPI score (Group A) and patients with 1.5-2.5 GPI score (Group B). HT was applied twice a week, 60 min per session, during RT by regional capacitive device (HY-DEEP 600WM system) at 13.56 MHz radiofrequency. RESULTS: Between June 2015 and June 2017, 15 patients and a total of 49 brain metastases were included in the protocol. All patients received all HT sessions as planned. RT and systemic therapy were also completed as prescribed. Tolerance to treatment was excellent and no toxicity was registered. Patients with HT effective treatment time longer than the median (W90time > 88%) showed better actuarial PFS at 6 and 12 months (100% and 66.7%, respectively) compared to those with less HT effective treatment time (50% and 0%, respectively) (p < 0.031). Median OS was 6 months (range 1-36 months). Stratification by GPI score showed a median OS of 3 months (CI 95% 2.49-3.51) in Group A and 8.0 months (CI 95% 5.15-10.41) in Group B (p = 0.035). CONCLUSIONS: Regional hyperthermia is a feasible and safe technique to be used in combination with RT in brain metastases patients, improving PFS and survival in poor prognostic brain metastasis patients.
PURPOSE: The aim of this study is to assess for the first time, the role of regional deep hyperthermia in combination with radiotherapy and systemic therapy in patients with poor prognosis of brain metastases (GPI ≤ 2.5). METHODS:Patients with confirmed cerebral metastases and classified as GPI score ≤ 2.5 were included in this prospective study. Pretreatment stratification was defined as patients with 0-1 GPI score (Group A) and patients with 1.5-2.5 GPI score (Group B). HT was applied twice a week, 60 min per session, during RT by regional capacitive device (HY-DEEP 600WM system) at 13.56 MHz radiofrequency. RESULTS: Between June 2015 and June 2017, 15 patients and a total of 49 brain metastases were included in the protocol. All patients received all HT sessions as planned. RT and systemic therapy were also completed as prescribed. Tolerance to treatment was excellent and no toxicity was registered. Patients with HT effective treatment time longer than the median (W90time > 88%) showed better actuarial PFS at 6 and 12 months (100% and 66.7%, respectively) compared to those with less HT effective treatment time (50% and 0%, respectively) (p < 0.031). Median OS was 6 months (range 1-36 months). Stratification by GPI score showed a median OS of 3 months (CI 95% 2.49-3.51) in Group A and 8.0 months (CI 95% 5.15-10.41) in Group B (p = 0.035). CONCLUSIONS: Regional hyperthermia is a feasible and safe technique to be used in combination with RT in brain metastasespatients, improving PFS and survival in poor prognostic brain metastasis patients.
Authors: C C Vernon; J W Hand; S B Field; D Machin; J B Whaley; J van der Zee; W L van Putten; G C van Rhoon; J D van Dijk; D González González; F F Liu; P Goodman; M Sherar Journal: Int J Radiat Oncol Biol Phys Date: 1996-07-01 Impact factor: 7.038
Authors: B G Salas-Salas; D J Domínguez-Nuez; R Cabrera; L Ferrera-Alayón; M Lloret; P C Lara Journal: Clin Transl Oncol Date: 2019-06-01 Impact factor: 3.405
Authors: Ludy C H W Lutgens; Peter C M Koper; Jan J Jobsen; Elzbieta M van der Steen-Banasik; Carien L Creutzberg; Hetty A van den Berg; Petronella B Ottevanger; Gerard C van Rhoon; Helena C van Doorn; Ruud Houben; Jacoba van der Zee Journal: Radiother Oncol Date: 2016-02-17 Impact factor: 6.280
Authors: J van der Zee; D González González; G C van Rhoon; J D van Dijk; W L van Putten; A A Hart Journal: Lancet Date: 2000-04-01 Impact factor: 79.321
Authors: Paul W Sperduto; Samuel T Chao; Penny K Sneed; Xianghua Luo; John Suh; David Roberge; Amit Bhatt; Ashley W Jensen; Paul D Brown; Helen Shih; John Kirkpatrick; Amanda Schwer; Laurie E Gaspar; John B Fiveash; Veronica Chiang; Jonathan Knisely; Christina Maria Sperduto; Minesh Mehta Journal: Int J Radiat Oncol Biol Phys Date: 2009-11-26 Impact factor: 7.038